Teva officer Mark Sabag (NYSE: TEVA) sells 144,180 ordinary shares

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag completed an open-market sale of 144,180 Ordinary Shares on May 1, 2026, at a weighted average price of $34.9918 per share. Following this sale, he directly holds 80,760 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.

Insider Trade Summary

Net Seller: 144,180 shares ($5,045,118)

Net Sell 1 txn

Insider Sabag Mark

Role See "Remarks"

Sold 144,180 shs ($5.05M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	144,180	$34.9918	$5.05M

Holdings After Transaction: Ordinary Shares — 80,760 shares (Direct, null)

Footnotes (1)

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 144,180 shares Weighted average sale price: $34.9918 per share Shares held after transaction: 80,760 shares +1 more

4 metrics

Shares sold 144,180 shares Open-market sale of Teva Ordinary Shares on May 1, 2026

Weighted average sale price $34.9918 per share Price across multiple trades between $34.935 and $35.07

Shares held after transaction 80,760 shares Direct ownership of Teva Ordinary Shares following the sale

Price range of trades $34.935–$35.07 Range of individual trade prices within the reported sale

Key Terms

American Depositary Shares, weighted average price, open-market sale

3 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	05/01/2026		S		144,180	D	$34.9918(2)	80,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.935 to $35.07, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Teva (TEVA) officer Mark Sabag report in this Form 4?

Teva officer Mark Sabag reported an open-market sale of 144,180 Ordinary Shares. The transaction occurred on May 1, 2026, and involved Teva’s Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.

How many Teva (TEVA) shares did Mark Sabag sell and at what price?

Mark Sabag sold 144,180 Teva Ordinary Shares in an open-market transaction. The weighted average sale price was $34.9918 per share, based on multiple trades executed between $34.935 and $35.07 during the transaction date.

How many Teva (TEVA) shares does Mark Sabag hold after this sale?

After the reported sale, Mark Sabag directly holds 80,760 Teva Ordinary Shares. This figure reflects his position immediately following the May 1, 2026 transaction disclosed in the Form 4 filing with the U.S. Securities and Exchange Commission.

What does the weighted average price mean in this Teva (TEVA) Form 4?

The weighted average price of $34.9918 means the 144,180 shares were sold in multiple trades at prices between $34.935 and $35.07. The reported figure averages those trades based on the number of shares executed at each price level.

Are Teva (TEVA) American Depositary Shares involved in this Form 4 transaction?

The filing states that Teva’s Ordinary Shares may be represented by American Depositary Shares, each currently equal to one Ordinary Share. The reported transaction is in Ordinary Shares, which can correspond directly to American Depositary Shares on this basis.